| P50 | author | Zeina Al-Mansour | Q92161449 |
| P2093 | author name string | Muthalagu Ramanathan | |
| | Jan Cerny | |
| P2860 | cites work | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 |
| | Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 | Q28271344 |
| | Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? | Q30414156 |
| | Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry | Q33374224 |
| | Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry | Q33384383 |
| | Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic | Q33566684 |
| | Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome | Q33813439 |
| | Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma | Q33824082 |
| | Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age | Q33838116 |
| | High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. | Q33956065 |
| | Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. | Q33978945 |
| | Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia | Q33990856 |
| | Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease | Q34022803 |
| | Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades | Q34358438 |
| | Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma | Q34971081 |
| | High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol | Q83277288 |
| | Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy | Q83389146 |
| | Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study | Q84412690 |
| | Peripheral blood stem cell collection in elderly patients | Q84435389 |
| | Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma | Q84585326 |
| | Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies | Q35554703 |
| | Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study | Q35849241 |
| | Practice variation in physician referral for allogeneic hematopoietic cell transplantation. | Q36547170 |
| | Autologous stem cell transplantation beyond 60 years of age. | Q36623644 |
| | Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 |
| | The changing prevalence of comorbidity across the age spectrum | Q36876774 |
| | Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors | Q36951734 |
| | Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. | Q36960349 |
| | Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). | Q37089928 |
| | Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. | Q37382627 |
| | Effects of aging on hematopoietic stem and progenitor cells | Q37509575 |
| | Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial | Q38388775 |
| | Validation of a combined comorbidity index | Q39605818 |
| | Future of cancer incidence in the United States: burdens upon an aging, changing nation | Q39983611 |
| | Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma | Q40082924 |
| | An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era | Q41127479 |
| | Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit | Q41896967 |
| | Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors | Q43974989 |
| | Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies | Q44447834 |
| | Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant | Q44637274 |
| | Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. | Q45250187 |
| | Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. | Q45933706 |
| | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States | Q46389618 |
| | Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older | Q46433183 |
| | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. | Q46438521 |
| | Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis | Q47237352 |
| | The Cost of Hematopoietic Stem-Cell Transplantation in the United States | Q47272843 |
| | Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable | Q48457773 |
| | Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway | Q49865664 |
| | Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. | Q51042978 |
| | Economics of hematopoietic cell transplantation. | Q51588444 |
| | Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. | Q53481866 |
| | Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. | Q53626155 |
| | Validation of a multidimensional evaluation scale for use in elderly cancer patients | Q59504113 |
| | Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program | Q59647417 |
| | A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 |
| | Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies | Q71975298 |
| | High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party | Q72144472 |
| | Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution | Q73704588 |
| | Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years | Q74502702 |
| | Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) | Q79233975 |
| | Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older | Q81374762 |
| | Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants | Q81817444 |
| | Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | Q82236404 |
| | Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma | Q83215929 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1055-1064 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns | |
| P478 | volume | 35 | |